Tailored Approach to Onset Time Onset varies based on deficiency severity, dosage, and individual health, ensuring a customized treatment plan
Water, Glycerin, Dipropylene Glycol, Butylene Glycol, Niacinamide, Tranexamic Acid, Glycereth-26, Propanediol, 1,2-Hexanediol, Hydroxyacetophenone, Xanthan Gum, Tromethamine, Carbomer, Ethylhexylglycerin, Adenosine, Disodium EDTA, Beta-Glucan, Glutathione, Polysorbate 20, Hydrolyzed Gardenia Florida Extract, Hydrolyzed Viola Tricolor Extract, Hydrolyzed Malt Extract, Lecithin, Hyaluronic Acid, Hydrolyzed Hyaluronic Acid, Sodium Hyaluronate, Nicotinoyl Hexapeptide-44, sh-Oligopeptide-1, sh-Polypeptide-4, sh-Polypeptide-16, sh-Polypeptide-1
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Any references to skin, collagen, extracellular matrix, or oxidative-stress pathways are provided only for research context and do not imply cosmetic or clinical use
By reducing NNMT catalytic activity, the compound allows researchers to evaluate how limiting nicotinamide methylation influences: In vitro and in vivo experimental models (non-clinical, non-human) have demonstrated that NNMT suppression leads to measurable changes in cellular energy markers and adipocyte behavior
